SPHK1 and neoplasm: Importantly, Lee et al. showed that FDA-approved SphK1-specific inhibitors (FTY720 or SKI-II) can overcome Enzalutamide-resistant CRPC tumor growth, suggesting that the repurposing of these small molecules has an immediate translational applicability to improve the outcome of NEPC patients to prolong their OS [135].